Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Betamethasone. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR3C1 known ✓ | P04150 | 9/20 | 1.00 |
| ▸ | HIF1A | Q16665 | 9/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 7/20 | 1.00 |
| ▸ | HSD17B10 | Q99714 | 4/20 | 1.00 |
| ▸ | NFKB1 | P19838 | 4/20 | 1.00 |
| ▸ | PGR | P06401 | 3/20 | 1.00 |
| ▸ | TSHR | P16473 | 2/20 | 1.00 |
| ▸ | AR | P10275 | 2/20 | 1.00 |
| ▸ | PMP22 | Q01453 | 2/20 | 1.00 |
| ▸ | MEN1 | O00255 | 1/20 | 1.00 |
| ▸ | CYP2D6 | P10635 | 1/20 | 1.00 |
| ▸ | KMT2A | Q03164 | 1/20 | 1.00 |
| ▸ | APEX1 | P27695 | 1/20 | 1.00 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 1.00 |
| ▸ | IKBKB | O14920 | 1/20 | 1.00 |
| ▸ | CHUK | O15111 | 1/20 | 1.00 |
| ▸ | ADRB2 | P07550 | 1/20 | 1.00 |
| ▸ | NR3C2 | P08235 | 1/20 | 1.00 |
| ▸ | PLA2G2A | P14555 | 1/20 | 1.00 |
| ▸ | NFKB2 | Q00653 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Betamethasone SCHEMBL13026138 | 1.00 | HIF1A (1.00) | HIF1ANR3C1CYP3A4HSD17B10NFKB1 | |
| Betamethasone SCHEMBL13046610 | 1.00 | HIF1A (1.00) | HIF1ANR3C1CYP3A4HSD17B10NFKB1 | |
| Betamethasone SCHEMBL5072889 | 1.00 | HIF1A (1.00) | HIF1ANR3C1CYP3A4HSD17B10NFKB1 | |
| Betamethasone SCHEMBL3392690 | 1.00 | HIF1A (1.00) | HIF1ANR3C1CYP3A4HSD17B10NFKB1 | |
| Betamethasone SCHEMBL24556970 | 1.00 | HIF1A (1.00) | HIF1ANR3C1CYP3A4HSD17B10NFKB1 | |
| Betamethasone SCHEMBL23022353 | 1.00 | HIF1A (1.00) | HIF1ANR3C1CYP3A4HSD17B10NFKB1 | |
| Betamethasone SCHEMBL20816248 | 1.00 | HIF1A (1.00) | HIF1ANR3C1CYP3A4HSD17B10NFKB1 | |
| Betamethasone SCHEMBL21790369 | 1.00 | HIF1A (1.00) | HIF1ANR3C1CYP3A4HSD17B10NFKB1 | |
| Betamethasone SCHEMBL21261932 | 1.00 | HIF1A (1.00) | HIF1ANR3C1CYP3A4HSD17B10NFKB1 | |
| Betamethasone SCHEMBL11911310 | 1.00 | HIF1A (1.00) | HIF1ANR3C1CYP3A4HSD17B10NFKB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230019140-A1 | COMBINATION TREATMENT FOR CANCER WITH ANTI-BCMA BINDING PROTEIN AND PROTEOSOME INHIBITOR | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2023-01-19 | — | — | US | disclosed |
| US-20220204638-A1 | Combination Therapies Comprising Daratumumab, Bortezomib, Thalidomide and Dexamethasone and Their Uses | JANSSEN BIOTECH INC (US) | 2022-06-30 | — | — | US | disclosed |
| US-20200397896-A1 | Combination Therapies Comprising Daratumumab, Bortezomib, Thalidomide and Dexamethasone and Their Uses | JANSSEN BIOTECH, INC. | 2020-12-24 | — | — | US | disclosed |
| US-20200268847-A1 | Methods of Treating Newly Diagnosed Multiple Myeloma with a Combination of An Antibody that Specifically Binds CD38, Lenalidomide and Dexamethasone | JANSSEN BIOTECH, INC. | 2020-08-27 | — | — | US | disclosed |
| WO-2019054822-A1 | ACTIVE SUBSTANCE-HEXAPEPTIDE COMPLEX AND COSMETIC COMPOSITION CONTAINING SAME | 애니젠 주식회사 | 2019-03-21 | — | — | WO | disclosed |
| US-7923441-B2 | Enhancement of activity and/or duration of action of soft anti-inflammatory steroids for topical or other local application | BODOR LABORATORIES, INC. | 2011-04-12 | — | — | US | disclosed |
| US-7923441-B2 | Enhancement of activity and/or duration of action of soft anti-inflammatory steroids for topical or other local application | BODOR LABORATORIES, INC. | 2011-04-12 | — | — | US | disclosed |
| US-20090239833-A1 | ENHANCEMENT OF ACTIVITY AND/OR DURATION OF ACTION OF SOFT ANTI-INFLAMMATORY STEROIDS FOR TOPICAL OR OTHER LOCAL APPLICATION | BODOR LABORATORIES, INC. | 2009-09-24 | — | — | US | disclosed |
| US-20090239833-A1 | ENHANCEMENT OF ACTIVITY AND/OR DURATION OF ACTION OF SOFT ANTI-INFLAMMATORY STEROIDS FOR TOPICAL OR OTHER LOCAL APPLICATION | BODOR LABORATORIES, INC. | 2009-09-24 | — | — | US | disclosed |
| US-7560448-B2 | Enhancement of activity and/or duration of action of soft anti-inflammatory steroids for topical or other local application | BODOR LABORATORIES, INC. | 2009-07-14 | — | — | US | disclosed |
| US-7560448-B2 | Enhancement of activity and/or duration of action of soft anti-inflammatory steroids for topical or other local application | BODOR LABORATORIES, INC. | 2009-07-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230019140-A1 | COMBINATION TREATMENT FOR CANCER WITH ANTI-BCMA BINDING PROTEIN AND PROTEOSOME INHIBITOR | SERPINA6, RBBP7, BCL6 | NR3C1 1480/4885HIF1A 2565/4885CYP3A4 4729/4885 |
| US-20200268847-A1 | Methods of Treating Newly Diagnosed Multiple Myeloma with a Combination of An Antibody that Specifically Binds CD38, Lenalidomide and Dexamethasone | CD22, CD2BP2, CD38 | NR3C1 96/4885HIF1A 2026/4885CYP3A4 4397/4885 |
| US-20200397896-A1 | Combination Therapies Comprising Daratumumab, Bortezomib, Thalidomide and Dexamethasone and Their Uses | SERPINA6, PTH1R, NR3C1 | NR3C1 3/4885HIF1A 494/4885CYP3A4 4168/4885 |
| US-20090239833-A1 | ENHANCEMENT OF ACTIVITY AND/OR DURATION OF ACTION OF SOFT ANTI-INFLAMMATORY STEROIDS FOR TOPICAL OR OTHER LOCAL APPLICATION | OXER1, ELOVL6, ELOVL3 | NR3C1 39/4885HIF1A 1572/4885CYP3A4 192/4885 |
| US-20220204638-A1 | Combination Therapies Comprising Daratumumab, Bortezomib, Thalidomide and Dexamethasone and Their Uses | CD22, IGLV6-57, SERPINA6 | NR3C1 5/4885HIF1A 598/4885CYP3A4 4238/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.